1、Yun-Ze Xu,Yu Zhu#. Conventional Chemotherapy and Emerging Targeted Therapy for AdvancedAdrenocortical Carcinoma. Anti-Cancer Agents in Medicinal Chemistry,2012;
2、Sheng Jy,He Hc,Zhu Y#,Shen Zj. Myxoid adrenocortical tumor：report of four cases. Chin Med J,2012;
3、Feng F, Zhu Y*, Wang X, Wu Y, Zhou W, Jin X, Zhang R, Sun F, Kasoma Z, Shen Z.. Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol.,2011 May;;185(5):1583-90.
4、Xu YZ, Zhu Y#, Shen ZJ, Sheng JY, He HC, Ma G, Qi YC, Zhao JP, Wu YX, Rui WB, Wei Q, Zhou WL, Xie X, Ning G. Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine,2011;40(3):445-51
5、ZHU Yu#, He HC, Yuan F, Zhang J, Rui WB, Zhao JP, Shen ZJ, Ning G. Heparanase-1 and Cyclooxygenase-2:prognostic indicators of malignancy Pheochromocytomas. Endocrine,2010;38:93-99
6、ZHU Yu#, He HC, Su TW, Wu YX, Wang WQ, Zhao JP, Shen Z, Zhang CY, Rui WB,ZhouWL,SunFK,NingG. Selective α1-adrenoceptor antagonist(controlled release tablets) in preoperative management of Pheochromocytoma.. Endocrine,2010;38:254-259
|
